The global chenodeoxycholic acid market size was USD XX Billion in 2022 and is likely to reach USD XX Billion by 2031, expanding at a CAGR of 6.8% during the forecast period, 2023–2031. The growth of the market is attributed to increasing demand for emulsifiers, organic acids, pharmaceuticals, and detergents in a variety of businesses throughout the world.
Chenodeoxycholic acid (CDCA) is a bile acid that is spontaneously created by the human liver and stored in the gall bladder until needed for dietary fat absorption. It is used to treat bile synthesis abnormalities caused by single enzyme deficiencies, peroxisomal diseases, and Zellweger syndrome. Oral bile acid treatment has been utilized in individuals with tiny cholesterol stones as well as those with bigger cholesterol gallstones who are unable or unwilling to perform the surgery.
However, CDCA causes diarrhea when it is used to dissolve gallstones, it has been explored as a potential therapy for constipation and has been found to enhance colonic transit and bowel function. Moreover, Giaconda, an Australian biotechnology company, has tested a Hepatitis C medication that combines chenodeoxycholic acid and bezafibrate.
New severe acute respiratory syndrome that is coronavirus disease has generated an unparalleled worldwide public health disaster. COVID-19 outbreak has three key implications on the global economy: disruption of supply chains and marketplaces, direct influence on production and demand, and financial impact on enterprises and financial markets.
Chenodeoxycholic Acid Market Trends, Drivers, Restraints, and Opportunities
- Growing demand for cholagogues and PSC drugs drives market during the forecast period.
- Rising population in developing countries such as China & India likely to propel the market expansion.
- Increasing number of gall stone cases throughout the world due to different factors such as obesity, hereditary disorders, and other medical diseases anticipated to boost the market growth.
- Cholic acid and related medications taken in excess can produce jaundice, which can lead to severe liver damage. This is projected to hinder market expansion in the coming years.
- CDCA is a natural substance with a short patent life in most places, resulting in limited availability and high costs for drug development. This is a major factor which hamper the market.
- Demand from food & beverage industries and pharmaceuticals anticipated to create lucrative opportunities for the market growth during the forecast period.
Scope of Chenodeoxycholic Acid Market Report
The report on the global chenodeoxycholic acid market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Chenodeoxycholic Acid Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Applications (Emulsifier, Organic Acid, Medicine, Detergents, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Tianjin NWS Biotechnology and Medicine; Shaanxi Top Pharm Chemical; Pharmazell; Haihang Industry; Dr Falk Pharma; Daewoong; Bruschettini; Suzhou Tianlu Bio-Pharmaceutical; and Zhongshan Belling Biotechnology
|
Chenodeoxycholic Acid Market Segment Insights
Organic Acid segment to expand at a considerable CAGR
On the basis of applications, the chenodeoxycholic acid market is segmented into emulsifier, organic acid, medicine, detergents, and others. The organic acid segment is projected to expand at a considerable CAGR during the forecast period, due to the high demand in food & beverages, textile industries, and pharmaceuticals. On the other hand, the emulsifier segment is anticipated to account for a major market share during the forecast period. The emulsifier agents have great demand in cosmetic industry as to form the emulsion.
Europe is anticipated to constitute a key market share
In terms of regions, the chenodeoxycholic acid market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Europe is expected to constitute a key share of the market during the projected period owing to high production of cholic acid. The region's huge number of manufacturers will help to drive regional market expansion. However, the market of Asia Pacific is anticipated to expand at a rapid pace during the forecast period due to increasing incidence of kidney failure, gallstones, and other kidney-related diseases.
Segments
The global chenodeoxycholic acid market has been segmented on the basis of
Applications
- Emulsifier
- Organic Acid
- Medicine
- Detergents
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Tianjin NWS Biotechnology and Medicine
- Shaanxi Top Pharm Chemical
- Pharmazell
- Haihang Industry
- Dr Falk Pharma
- Daewoong
- Bruschettini
- Suzhou Tianlu Bio-Pharmaceutical
- Zhongshan Belling Biotechnology
Competitive Landscape
Key players competing in the chenodeoxycholic acid market are Tianjin NWS Biotechnology and Medicine; Shaanxi Top Pharm Chemical; Pharmazell; Haihang Industry; Dr Falk Pharma; Daewoong; Bruschettini; Suzhou Tianlu Bio-Pharmaceutical; and Zhongshan Belling Biotechnology
The market is extremely fragmented due to the existence of a significant number of global and local competitors. Furthermore, international businesses' consolidation actions are expected to boost rivalry among emerging and local market competitors. The market's top companies are always striving to expand their market share.
Request For Customization
Enquiry Before Buying
Speak With Analyst
